Figure 2
Figure 2. pEFS according to chimerism status including MC patients with and without immunotherapy. Kaplan-Meier estimates of pEFS for patients with CC and MC (pEFS, log-rank test, P < .0001; Figure 2A). CC patients: n = 51; censored, n = 9. MC patients: n = 20; censored, n = 14. Kaplan-Meier analyses of pEFS of immunotherapy-treated MC patients and patients with MC who did not receive immunotherapy (pEFS, log-rank test, P = .0009; Figure 2B). MC patients with immunotherapy: n = 13; censored, n = 7, pEFS = 0.46, 95% CI = 0.19-0.70. MC patients without immunotherapy: n = 7; censored, n = 7, pEFS = 0.00.

pEFS according to chimerism status including MC patients with and without immunotherapy. Kaplan-Meier estimates of pEFS for patients with CC and MC (pEFS, log-rank test, P < .0001; Figure 2A). CC patients: n = 51; censored, n = 9. MC patients: n = 20; censored, n = 14. Kaplan-Meier analyses of pEFS of immunotherapy-treated MC patients and patients with MC who did not receive immunotherapy (pEFS, log-rank test, P = .0009; Figure 2B). MC patients with immunotherapy: n = 13; censored, n = 7, pEFS = 0.46, 95% CI = 0.19-0.70. MC patients without immunotherapy: n = 7; censored, n = 7, pEFS = 0.00.

Close Modal

or Create an Account

Close Modal
Close Modal